Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant-adenovirus-mediated gene transfer

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 4925-4936

  Fukazawa, Takuya ^a   Maeda, Yutaka ^b   Matsuoka, Junji ^c   Ono, Toshiro ^c   Mominoki, Katsumi ^c   Yamatsuji, Tomoki ^a   Shigemitsu, Kaoru ^a   Morita, Ichiro ^a   Murakami, Ichiro ^d   Tanaka, Hirotoshi ^e   Durbin, Mary L ^f   Naomoto, Yoshio ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c OKAYAMA UNIVERSITY   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CC10; Gene transfer; Intratracheal instillation; Kras mutation; Lung cancer; Pulmonary surfactant

Indexed keywords

ADENOVIRUS VECTOR; CCAAT ENHANCER BINDING PROTEIN ALPHA; LUNG SURFACTANT; SURFACTANT TA; TELOMERASE REVERSE TRANSCRIPTASE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CYTOTOXICITY; DRUG ACTIVITY; GENE MUTATION; GENE TARGETING; GENE TRANSFER; IN VIVO STUDY; LUNG ALVEOLUS; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION;

ADENOCARCINOMA; ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; BREAST NEOPLASMS; CATTLE; CELL LINE, TUMOR; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, RAS; GENETIC VECTORS; HELA CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED ICR; MICE, TRANSGENIC; MUTATION; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS, GENETIC; PULMONARY SURFACTANTS;

EID: 78751475672     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Flotte TR and Laube BL: Gene therapy in cystic fibrosis. Chest 120: 124S-131S.2001.
2. Griesenbach U, Ferrari S, Geddes DM and Alton EW: Gene therapy progress and prospects: cystic fibrosis. Gene Ther 9: 1344-1350,2002. (Pubitemid 35244159)
3. Bou-Gharios G, Wells DJ, Lu QL, Morgan JE and Partridge T: Differential expression and secretion of alpha 1 anti-trypsin between direct DNA injection and implantation of transfected myoblast. Gene Ther 6: 1021-1029, 1999. (Pubitemid 29295207)
4. De B, Heguy A, Leopold PL, Wasif N, Korst RJ, Hackett NR and Crystal RG: Intrapleural administration of a serotype 5 adeno-associated virus coding for alpha 1-antitrypsin mediates persistent, high lung and serum levels of alphal-antitrypsin. Mol Ther 10: 1003-1010, 2004. (Pubitemid 39625244)
5. Behera AK, Kumar M, Lockey RF and Mohapatra SS: Adenovirus-mediated interferon gamma gene therapy for allergic asthma: involvement of interleukin 12 and STAT4 signaling. Hum Gene Ther 13: 1697-1709, 2002. (Pubitemid 35191745)
6. Nakanishi A, Morita S, Iwashita H, Sagiya Y, Ashida Y, Shirafuji H, Fujisawa Y, Nishimura O and Fujino M: Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma. Proc Natl Acad Sci USA 95: 5175-5180, 2001. (Pubitemid 32397102)
7. Champion HC, Bivalacqua TJ, Toyoda K, Heistad DD, Hyman AL and Kadowitz PJ: In vivo gene transfer of pre-procalcitonin generelated peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse. Circulation 101: 923-930, 2000.
8. Weill D, Mack M, Roth J, Swisher S, Proksch S, Merritt J and Nemunaitis J: Adenoviral-mediated p53 gene transfer to nonsmall cell lung cancer through endobronchial injection. Chest 118: 966-970, 2000.
9. Merritt JA, Roth JA and Logothetis CJ: Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. Semin Oncol 25: 105-114, 2001.
10. Sinn PL, Burnight ER and McCray PB Jr.: Progress and prospects: prospects of repeated pulmonary administration of viral vectors. Gene Ther 16: 1059-1065, 2009.
11. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB Jr, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D and Waugh MK: Adenovirus-mediated p53 gene transfer in advanced non-small cell lung cancer. J Natl Cancer Inst 91:763-771, 1999.
12. Nemunaitis J, Swisher SG, Timmons T Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J and Roth J: Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 18: 609-622, 2000.
13. JobeAH,UedaT,WhitsettJA,TrapnellBCandIkegamiM: Surfactantenhancesadenovirus-mediatedgeneexpressioninrabbitlungs.GeneTher3: 775-779,1996.(Pubitemid26326682)
14. Korfhagen TR, Bruno MD, Ross GF, Huelsman KM, Ikegami M, Jobe AH, Wert SE, Stripp BR, Morris RE, Glasser SW, Bachurski CJ, Iwamoto HS and Whitsett JA: Altered surfactant function and structure in SP-A gene targeted mice. Proc Natl Acad Sci USA 93: 9594-9599, 1996.
15. Buckingham S and Avery ME: Time of appearance of lung surfactant in the foetal mouse. Nature 193: 688-689, 1962.
16. Klaus M, Reiss OK, To Oley WH, Piel C and Clements JA: Alveolar epithelial cell mitochondria as source of the surfaceactive lung lining. Science 137: 750-751,1962.
17. FujiwaraT,MaetaH,ChidaS,MoritaT,WatabeYandAbeT: Artificialsurfactanttherapyinhyaline-membranedisease.Lancet1:55-59,1980. (Pubitemid10199398)
18. Clements JA and Avery ME: Lung surfactant and neonatal respiratory distress syndrome. Am J Respir Crit Care Med 157: S59-66,1998.
19. Whitsett JA and Weaver TE: Hydrophobic surfactant proteins in lung function and disease. N Engl J Med 347: 2141-2148, 2002. (Pubitemid 36015127)
20. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, Whitsett JA, Koretsky A and Varmus HE: Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15: 3249-3262, 2001.
21. Riely GJ, Marks J and Pao W: KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6: 201-205, 2009.
22. Stripp BR, Sawaya PL, Luse DS, Wikenheiser KA, Wert SE, Huffman JA, Lattier DL, Singh G, Katyal SL and Whitsett JA: cis-acting elements that confer lung epithelial cell expression of the CC10 gene. J Biol Chem 267: 14703-14712, 1992.
23. Twu YC, Chen CP, Hsieh CY, Tzeng CH, Sun CF, Wang SH, Chang MS and Yu LC: I branching formation in erythroid differentiation is regulated by transcription factor C/EBPalpha. Blood 110: 4526-4534, 2007.
24. Fukazawa T, Maeda Y, Sladek FM and Owen-Schaub LB: Development of a cancer-targeted tissue-specific promoter system. Cancer Res 64: 363-369, 2004. (Pubitemid 38114119)
25. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW and Vogelstein B: A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514, 1998. (Pubitemid 28145972)
26. Takahashi A, Nemoto T and Fujiwara T: Biophysical properties of protein-free, totally synthetic pulmonary surfactants, ALEC and Exosurf, in comparison with surfactant TA. Acta Paediatr Jpn 36: 613-618, 1994.
27. Epaud R, Ikegami M, Whitsett JA, Jobe AH, Weaver TE and Akinbi HT: Surfactant protein B inhibits endotoxin-induced lung inflammation. Am J Respir Cell Mol Biol 25: 373-378, 2003. (Pubitemid 36238015)
28. Wert SE, Dey CR, Blair PA, Kimura S and Whitsett JA: Increased expression of thyroid transcription factor-1 (TTF-1) in respiratory epithelial cells inhibits alveolarization and causes pulmonary inflammation. Dev Biol 242: 75-87, 2002. (Pubitemid 34163972)
29. Weiss DJ, Mutlu GM, Bonneau L, Mendez M, Wang Y, Dumasius V and Factor P: Comparison of surfactant and perfluorochemical liquid enhanced adenovirus-mediated gene transfer in normal rat lung. Mol Ther 6: 43-49, 2002. (Pubitemid 36124269)
30. KatkinJP,HusserRC,LangstonCandWeltySE: Exogenoussurfactantenhancesthedeliveryofrecombinantadenoviralvectors-thelung. HumGeneTher8:171-176,1997.(Pubitemid27089191)
31. Liu MY, Wang LM, Li E and Enhorning G: Pulmonary surfactant will secure free airflow through a narrow tube. J Appl Physiol 71: 742-748, 1991.
32. Rubin BK, Ramirez O and King M: Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy. Chest 101: 1080-1085, 1992.
33. Wu H, Kuzmenko A, Wan S, Schaffer L, Weiss A, Fisher JH, Kim KS and McCormack FX: Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest 111: 1589-1602, 2003. (Pubitemid 38063292)
34. Casals C: Role of surfactant protein A (SP-A)/lipid interactions for SP-A functions in the lung. Pediatr Pathol Mol Med 20: 249-268, 2001. (Pubitemid 32577742)
35. JobeAH,IkegamiM,YeiS,WhitsettJAandTrapnellB: Surfactanteffectsonaerosolizedandinstilledadenoviralmediatedgenetransfer. HumGeneTher7:697-704,1996.(Pubitemid26125839)
36. Kobinger GP, Weiner DJ, Yu QC and Wilson JM: Filoviruspseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 19: 225-230, 2001.
37. Flotte TR, Schwiebert EM, Zeitlin PL, Carter BJ and Guggino WB: Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adenoassociated virus serotype 2 gene therapy. Hum Gene Ther 16: 921-928, 2005.
38. LeeHY,SuhYA,LeeJI,HassanKA,MaoL,ForceT,GilbertBE,JacksTandKurieJM.: InhibitionofoncogenicK- rassignalingbyaerosolizedgenedeliveryinamousemodelofhumanlungcancer. ClinCancerRes5:2970-2975,2002.(Pubitemid35025746)
39. Hwang SK, Lim HT, Minai-Tehrani A, Lee ES, Park J, Park SB, Beck GR Jr. and Cho MH: Repeated aerosol delivery of carboxyl-terminal modulator protein suppresses tumor in the lungs of K-rasLA 1 mice. Am J Respir Crit Care Med 179: 1131-1140, 2009.